Your browser doesn't support javascript.
loading
Exploring the performance of during-treatment substance use outcome measures in predicting longer-term psychosocial functioning and post-treatment abstinence.
Brandt, Laura; Hu, Mei-Chen; Nunes, Edward V; Campbell, Aimee N C.
Affiliation
  • Brandt L; Department for Psychology, The City College of New York, New York, NY, USA. Electronic address: lbrandt@ccny.cuny.edu.
  • Hu MC; Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, USA.
  • Nunes EV; Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, USA.
  • Campbell ANC; Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA; Division on Substance Use Disorders, New York State Psychiatric Institute, New York, NY, USA.
Drug Alcohol Depend ; 248: 109918, 2023 Jul 01.
Article de En | MEDLINE | ID: mdl-37224673
ABSTRACT

BACKGROUND:

The selection of appropriate efficacy endpoints in clinical trials has been a long-standing challenge for the substance use disorder field. Using data from a large, multi-site National Drug Abuse Treatment Clinical Trials Network trial (CTN-0044; n=474), this secondary data analysis aimed to explore whether specific proximal (during-treatment) substance use outcome measures predict longer-term improvements in psychosocial functioning and post-treatment abstinence, and whether predictions vary depending on the specific substance (cannabis, cocaine/stimulants, opioids, and alcohol).

METHODS:

Generalized linear mixed models examined associations between six during-treatment substance use outcome measures and social functioning impairment (Social Adjustment Scale Self-Report) and severity of psychiatric symptoms (Brief Symptom Inventory-18) at end-of-treatment, and 3- and 6-months after treatment as well as post-treatment abstinence.

RESULTS:

Maximum days of consecutive abstinence, proportion of days abstinent, ≥3 weeks of continuous abstinence, and the proportion of urine specimens negative for the primary substance were associated with post-treatment psychiatric and social functioning improvement and abstinence. However, only the effects of abstinence during the last 4 weeks of the treatment period on all three post-treatment outcomes was stable over time and did not differ between primary substance groups. In contrast, complete abstinence during the 12-week treatment period was not consistently associated with functioning improvements.

CONCLUSIONS:

Substance use outcome measures capturing the duration of primary substance abstinence during treatment are suitable predictors of post-treatment abstinence and longer-term psychosocial functioning improvement. Binary outcomes, such as end-of-treatment abstinence, may be particularly stable predictors and attractive given their ease of computation and straightforward clinical interpretability.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Troubles liés à une substance / Fonctionnement psychosocial Type d'étude: Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Drug Alcohol Depend Année: 2023 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Troubles liés à une substance / Fonctionnement psychosocial Type d'étude: Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Drug Alcohol Depend Année: 2023 Type de document: Article